INOTEK PHARMACEUTICALS CORP's ticker is ITEK and the CUSIP is 45780V102. A total of 69 filers reported holding INOTEK PHARMACEUTICALS CORP in Q1 2017. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,049,000 | +46.7% | 100,441 | -75.0% | 0.12% | +20.6% |
| Q3 2017 | $715,000 | -6.3% | 401,764 | 0.0% | 0.10% | -21.5% |
| Q2 2017 | $763,000 | -5.1% | 401,764 | 0.0% | 0.13% | -17.2% |
| Q1 2017 | $804,000 | -67.2% | 401,764 | 0.0% | 0.16% | -74.7% |
| Q4 2016 | $2,451,000 | -35.7% | 401,764 | 0.0% | 0.62% | 0.0% |
| Q3 2016 | $3,809,000 | +104.8% | 401,764 | +60.7% | 0.62% | +28.4% |
| Q2 2016 | $1,860,000 | +0.5% | 250,000 | 0.0% | 0.48% | +20.4% |
| Q1 2016 | $1,850,000 | -54.6% | 250,000 | -30.6% | 0.40% | -32.8% |
| Q4 2015 | $4,079,000 | +47.1% | 360,000 | +22.0% | 0.60% | +68.6% |
| Q3 2015 | $2,773,000 | +48.9% | 295,000 | -22.4% | 0.35% | +94.5% |
| Q2 2015 | $1,862,000 | -14.1% | 380,000 | -5.0% | 0.18% | -19.5% |
| Q1 2015 | $2,168,000 | – | 400,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Devon Park Associates, LLC | 3,243,709 | $36,751,000 | 100.00% |
| RHO CAPITAL PARTNERS INC | 2,627,790 | $29,773,000 | 10.24% |
| Private Capital Advisors, Inc. | 341,000 | $3,864,000 | 1.67% |
| NEXTHERA CAPITAL LP | 42,000 | $476,000 | 0.68% |
| SPHERA FUNDS MANAGEMENT LTD. | 360,000 | $4,079,000 | 0.60% |
| SENZAR ASSET MANAGEMENT, LLC | 309,600 | $3,507,768,000 | 0.39% |
| Graticule Asia Macro Advisors LLC | 148,000 | $1,676,000 | 0.27% |
| FT Options LLC | 26,421 | $299,000 | 0.22% |
| EAM Investors, LLC | 128,911 | $1,461,000 | 0.19% |
| Tekla Capital Management LLC | 425,000 | $4,815,000 | 0.18% |